This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

This study has been completed.
Information provided by:
Prana Biotechnology Limited Identifier:
First received: May 8, 2007
Last updated: January 13, 2008
Last verified: January 2008
The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.

Condition Intervention Phase
Alzheimer's Disease Drug: PBT2 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Prana Biotechnology Limited:

Primary Outcome Measures:
  • Safety [ Time Frame: Study duration ]

Secondary Outcome Measures:
  • Change from baseline in biomarkers; Change from baseline in cognitive and global function scales [ Time Frame: Study duration ]

Estimated Enrollment: 80
Study Start Date: December 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   56 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of probable early Alzheimer's disease
  • stable dose of acetylcholinesterase inhibitor
  • community dwelling
  • stable medical condition

Exclusion Criteria:

  • unstable and significant medical conditions
  • recurrent major psychiatric disorder
  • treatment with memantine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00471211

Australia, New South Wales
Sydney, New South Wales, Australia, 2031
Sydney, New South Wales, Australia, 2077
Australia, South Australia
Adelaide, South Australia, Australia, 5011
Australia, Victoria
Melbourne, Victoria, Australia, 3081
Melbourne, Victoria, Australia, 3101
Melbourne, Victoria, Australia, 3146
Melbourne, Victoria, Australia, 3199
Falkoping, Sweden, 521 85
Kalix, Sweden, 952 81
Kalmar, Sweden, 391 85
Lund, Sweden, 85
Malmo, Sweden, 205 20
Stockholm, Sweden, 112 98
Umea, Sweden, 901 85
Uppsala, Sweden, 751 85
Sponsors and Collaborators
Prana Biotechnology Limited
Principal Investigator: Lars Lannfelt, Professor Uppsala University Hospital, Sweden
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00471211     History of Changes
Other Study ID Numbers: PBT2-201
Study First Received: May 8, 2007
Last Updated: January 13, 2008

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on August 18, 2017